Highest-materiality recent filing
Enliven reports Q1 net loss of $23.6M; cash $452.4M; ELVN-001 Phase 1 data mid-2026
Net loss of $23.6M in Q1 2026 vs. $28.5M in Q1 2025; R&D spend $20.7M.
Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%
Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.
Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3
Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.
Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline
Richard Fair appointed President, CEO and board member, effective December 11, 2025.
Enliven Therapeutics Q3 2025 net loss $20.1M; completed Phase 1b enrollment for ELVN-001 in CML
Completed enrollment of randomized Phase 1b cohorts of ENABLE trial of ELVN-001 in CML; on track for Phase 3 pivotal trial in 2026.
Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001
Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.
Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate
Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.
Elected Class II directors: Rahul D. Ballal (36,870,420 for), Jake Bauer (37,250,826 for), Andrew Phillips (31,957,928 for).
Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants
Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.
Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated
47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.
Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M
Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.
Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025
Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).
Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks
Cash $291.8M as of Sept 30, 2024; runway into late 2026.
Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.
Enliven shareholders approve 2.9M share increase in equity plan and officer exculpation amendment
Stockholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 2,900,000.
Enliven Therapeutics appoints director Lori Kunkel to Nominating Committee
Dr. Lori Kunkel appointed to Nominating and Corporate Governance Committee effective May 29, 2024.
Enliven Therapeutics Q1 net loss $22.7M; ELVN-001 Phase 1 shows 44% MMR at 12 weeks
Net loss of $22.7M for Q1 2024 vs $14.7M in Q1 2023; cash, equivalents & marketable securities $320.5M.
Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks
Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.
Enliven Therapeutics appoints Dr. Lori Kunkel to Board of Directors
Dr. Kunkel appointed as Class III director, term expiring at 2026 annual meeting.
Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026
Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.
Enliven reports 2023 net loss $71.6M; cash $253M; ELVN-001 data due Q2 2024
Net loss of $71.6M for full year 2023, up from $37.7M in 2022; R&D spend $64.6M.
On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.
Max materiality 0.85 · Median 0.60 · Most common event earnings